

Outcomes ≥ 1 year after transitioning from treatment with ibrutinib (ibru) in the ASPEN study to zanubrutinib (zanu)

Authors: Christian Buske,¹ Ramón García-Sanz,² Roger G. Owen,³ Wojciech Jurczak,⁴ Meletios A. Dimopoulos,⁵ Helen McCarthy,⁶ Gavin Cull,⁷ Stephen Opat,⁸ Jorge J. Castillo,⁹ Marie José Kersten,¹⁰ Björn E. Wahlin,¹¹ Sebastian Grosicki,¹² Radha Prathikanti,¹³ Tian Tian,¹⁴ Heather Allewelt,¹⁵ Aileen Cohen,¹⁶ Constantine S. Tam¹⁷

Affiliations: ¹Institute of Experimental Cancer Research, Comprehensive Cancer Center, Ulm University Hospital, Ulm, Germany; ²Hospital Universitario de Salamanca, Salamanca, Spain; ³St. James's University Hospital, Leeds, UK; ⁴Maria Skłodowska-Curie National Research Institute of Oncology, Kraków, Poland; ⁵General Hospital of Athens-Alexandra, Llisia, Greece; ⁶Royal Bournemouth Hospital, Bournemouth, UK; ⁷Sir Charles Gairdner Hospital, Nedlands, Australia; ⁸Lymphoma Research Group, School of Clinical Sciences at Monash Health, Monash University, Clayton, Australia; ⁹Dana-Farber Cancer Institute, Harvard Medical School, Boston, USA; ¹⁰Amsterdam University Medical Centers, University of Amsterdam, Amsterdam, Netherlands; ¹¹Karolinska Universitetssjukhuset Solna, Solna, Sweden; ¹²School of Public Health, Medical University of Silesia, Katowice, Poland; ¹³BeiGene USA Inc, San Mateo, CA, USA; ¹⁴BeiGene USA Inc, San Mateo, CA, USA; ¹⁵BeiGene USA Inc, San Mateo, CA, USA; ¹⁶BeiGene USA Inc, San Mateo, CA, USA; ¹⁷Alfred Hospital and Monash University, Melbourne, Australia.

ABSTRACT

Introduction: ASPEN (NCT03053440; phase 3) compared the BTK inhibitor (BTKi) zanu with ibru in patients (pts) with MYD88-mutated Waldenström macroglobulinemia (WM). LTE1 (NCT04170283) is a zanu long-term extension study. We report clinical outcomes ≥ 1 yr after transition from ibru in ASPEN to zanu in LTE1.

Methods: In LTE1, ibru-treated pts from ASPEN began 320 mg/day zanu. Disease response was assessed every 6 months by modified Owen criteria or as “no evidence of progressive disease” at investigator discretion. Safety/efficacy outcomes were analyzed ad hoc.

Results: Between Jun 26, 2020 and Jun 23, 2022, 47 ibru-treated pts from ASPEN enrolled in LTE1; most (79%) had relapsed/refractory WM prior to ASPEN. At LTE1 enrollment, median age was 73 yrs; median time from ASPEN discontinuation to zanu initiation was 0.07 months. As of Jun 23, 2023, 40 pts (85%) remained on study treatment. Median treatment duration was 50.4 months for ibru prior to transition and 15.3 months for zanu. During LTE1, grade ≥ 3 /serious treatment-emergent AEs (TEAEs) occurred in 23%/13% of pts. Infections (6.4%; all COVID-19) were the only grade ≥ 3 TEAEs in >2 pts; no serious TEAEs affected >2 pts. Most ibru TEAEs of interest for BTKis did not recur/worsen after zanu transition (except infections [n=3, all COVID-19], anemia [n=1], neutropenia [n=1]). Six of 7 pts with cardiovascular AEs (8 events) in LTE1 had ≥ 1 ibru-emergent cardiovascular AE during ASPEN. No worsening or new hypertension occurred after zanu transition. There was no recurrence or worsening of atrial fibrillation (AF)/flutter; 1 new AF case occurred (LTE1 day 12) in a pt with extensive cardiovascular history and concurrent pericarditis (LTE1 day 10). No cardiovascular TEAE led to death in LTE1. Two deaths occurred (both due to COVID-19). Overall response at end of ASPEN was maintained or improved at BOR in LTE1 in 96% (n=44/46) of efficacy-evaluable pts. Median [IgM] change was -36 mg/dL; [IgM] was stable/decreased in 29 pts (73%) from last ASPEN response assessment to BOR in LTE1.

Conclusions: Following zanu transition, at median ibru treatment duration of 50.4 months, most ibru-emergent TEAEs of interest for BTKis did not recur/worsen at 15-months median zanu treatment duration. Response was maintained or improved in 96% (n=44/46) of efficacy-evaluable pts. Although limited, the data suggest that transitioning ibru-tolerant pts with WM to zanu does not compromise safety or efficacy; long-term follow-up is ongoing.